From: Growth hormone treatment improves final height in children with X-linked hypophosphatemia
Time points of follow-up | Patients treated with rhGH (n = 34) | Patients non treated with rhGH (n = 29) | ||
---|---|---|---|---|
Age, years | Height SDS | Age, years | Height SDS | |
Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | |
Birth | – | − 0.5 ± 1.9 | – | 0.5 ± 1.2 |
Diagnosis | 3.5 ± 3.4 | − 2.2 ± 1.2 | 2.6 ± 2.6 | − 0.8 ± 1.6 |
Start of rhGH | 9.8 ± 3.5 | − 2.4 ± 0.9 | 9.8 ± 0.0 | − 0.7 ± 0.9 |
After 2 years of rhGH | 11.8 ± 3.4 | − 1.4 ± 0.7 | 11.9 ± 0.0 | − 0.9 ± 0.9 |
At the end of rhGH | 14.2 ± 3.1 | − 1.2 ± 0.9 | 14.2 ± 0.0 | − 1.1 ± 1.1 |
Final height | 18.3 ± 3.2 | − 1.3 ± 0.9 | 16.9 ± 2.1 | − 1.2 ± 1.1 |
165.5 ± 6.4 cm in boys 155.5 ± 6.3 cm in girls | 165.4 ± 6.8 cm in boys 153.7 ± 7.8 cm in girls | |||
Height gain at the end of rhGH | 1.2 ± 0.7 | – | – | |
Height gain at final height | 1.2 ± 0.9 | – | – |